N-ethyl-1-methylpiperidin-4-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-ethyl-1-methylpiperidin-4-amine
• 化学式: C₈H₁₈N₂
• mdl: MFCD07801141
• 分子量: 142.24
• InChiKey: GJCMPLHRWWWPHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-[4-(4-fluorophenylamino)pyrimidin-2-ylamino]benzenesulfonyl chloride hydrochloride 、 N-ethyl-1-methylpiperidin-4-amine 以100 mg of expected product are thus obtained的产率得到4-({4-[(4-fluorophenyl)amino]pyrimidin-2-yl}amino)-N-ethyl-N-(1-methylpiperidin-4-yl)benzene-sulfonamide
  参考文献：
  名称：

  Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors

  摘要：

  本公开涉及式(I)的化合物：其中R1-R5，A和Y如本公开所定义，以及包含所述化合物的组合物，制备所述化合物的方法和使用它们的方法。

  公开号：

  US20080269170A1

文献信息

• BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20160333009A1

  公开（公告）日：2016-11-17

  The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDOL) inhibitors of Formula I: or pharmaceutically acceptable salts thereof, in which X, L, n, m, R 1 , R 2a , R 2b , R n , R m , and R t are as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1.

  本公开提供了式I的吲哌酮2,3-二氧化酶1（IDOL）抑制剂： 或其药学上可接受的盐，其中X、L、n、m、R 1 、R 2a 、R 2b 、R n 、R m 和R t 如本文所定义，以及包括式I化合物的药物组合物，或其药学上可接受的盐，并使用这些方法来治疗由IDO1介导的疾病。
• EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
  申请人：SAREPTA THERAPEUTICS, INC.

  公开号：US20160040162A1

  公开（公告）日：2016-02-11

  Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.

  抗义RNA分子能够结合到人类肌营养不良蛋白基因中的特定靶位点，诱导外显子53跳跃。
• FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF
  申请人：Sarepta Therapeutics, Inc.

  公开号：US20140330006A1

  公开（公告）日：2014-11-06

  Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3′ and/or 5′-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

  提供了包含修改的亚单位间连接和/或修改的3'和/或5'-末端基团的功能修饰寡核苷酸类似物。所公开的化合物对于治疗需要抑制蛋白质表达或纠正异常mRNA剪接产物以产生有益治疗效果的疾病是有用的。
• HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：Ren Pingda

  公开号：US20120122838A1

  公开（公告）日：2012-05-17

  Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

  调节激酶活性的化合物和药物组合物，包括PI3激酶活性，以及与激酶活性相关的疾病和病况的化合物、药物组合物和治疗方法在此进行描述。
• THIAZOLYL-DIHYDRO-QUINAZOLINE
  申请人：Brandl Trixi

  公开号：US20070244104A1

  公开（公告）日：2007-10-18

  Disclosed are thiazolyl-dihydro-quinazolines of general formula (I) wherein the groups R 1 to R 4 have the meanings given in the claims and specification, the isomers thereof, and processes for preparing these compounds and their use as pharmaceutical compositions.

  揭示了一般式（I）的噻唑基-二氢喹唑啉化合物，其中基团R1至R4具有权利要求和说明书中给定的含义，其异构体，以及制备这些化合物的过程以及它们作为药物组成物的用途。